Kezar Life Sciences, Inc. · NASDAQ:KZR

Kezar Life Sciences — Technical Presentation (2023)

11 slides from Kezar Life Sciences's technical presentation, 2023

  1. Slide 1: Zetomipzomib demonstrates anti-inflammatory and immunomodulatory potential in active lupus

    Lupus nephritis-clinical: LO-017 Zetomipzomib (KZR-616) demonstrates anti-inflammatory and immunomodulatory potential in patients with active lupus with or without lupus nephritis: Results from the open-label Phase 1b/2 MISSION study Brad Rovin1, Amit Saxena2, Richard Leff3, Eunmi Park 3, Noreen R.

  2. Slide 2: Zetomipzomib (KZR-616): A First-in-Class, Small Molecule Selective Immunoproteasome Inhibitor

    Zetomipzomib (KZR-616): A First-in-Class, Small Molecule Selective Immunoproteasome Inhibitor What is immunoproteasome? TNF-α • Immunoproteasomes are abundantly expressed in immune IL-6 effector cells (e.g., T cells, B cells) Macrophage IL-23 IFN-α • Increased expression of the immunoproteasome is o

  3. Slide 3: MISSION Phase 1b: Study Design and Baseline Characteristics

    MISSION Phase 1b: Study Design and Baseline Characteristics • Open-label dose-escalation study to evaluate the safety and tolerability of zetomipzomib in patients with SLE ± LN Phase 1b: Study Schema Zetomipzomib (N=47) Age, year, mean (SD) 50.6 (13.5) Sex, n (%) Female 45 (95.7) Race, n (%) White 3

  4. Slide 4: MISSION Phase 1b: SLE Disease Activity Scores and Safety

    MISSION Phase 1b: SLE Disease Activity Scores and Safety SLE Disease Activity Scores Summary of Adverse Events Instrument, MISSION Phase 1b Adverse Events, n (%) MISSION Phase 1b mean (SD) n=35 Zetomipzomib N=47 Baseline Week 13 (EOT) Week 25 (EOS) SLEDAI-2K 9.1 (2.8) 6.6 (2.6) 7.1 (2.6) Most common

  5. Slide 5: MISSION Phase 2: Study Design and Baseline Characteristics

    MISSION Phase 2: Study Design and Baseline Characteristics • Open-label study to evaluate the efficacy and safety of zetomipzomib in patients with active proliferative LN (Class III or IV ± Class V) with 24-hour urine protein to creatinine ratios (UPCR) ≥1.0 mg/mg despite stable background therapy *

  6. Slide 6: Zetomipzomib Treatment Demonstrated Clinically Meaningful Renal Responses

    MISSION Phase 2: Zetomipzomib Treatment Demonstrated Clinically Meaningful Renal Responses (Evaluable Population, n=17) 17 1 16 2 2 Increase/no reduction 3 15 16 Primary UPCR reduction 0% to <25% 14 2 (94.1%) 15 13 2 Endpoint (88.2%) UPCR reduction 25% to 50% Number of Patients 12 2 UPCR reduction ≥

  7. Slide 7: Median UPCR Was Reduced to 0.32 mg/mg by the End of Study

    MISSION Phase 2: Median UPCR Was Reduced to 0.32 mg/mg by the End of Study (Evaluable Population, n=17) 2 1.88 1.8 Baseline Median UPCR (mg/mg) 1.6 57% 1.4 1.18 reduction 1.2 83% 1 reduction 0.8 0.81 0.81 0.6 0.4 0.4 0.32 0.32 0.2 0 Baseline W13 W25 (EOT) W29 W37 (EOS) ≤0.7 target goal based on the

  8. Slide 8: MISSION Phase 2: Other Efficacy Data

    MISSION Phase 2: Other Efficacy Data • Stable eGFR over 9 months of observation • By Week 13, 82.4% (14/17) of patients achieved a daily glucocorticoid dose of ≤10 mg and a 58% reduction in mean daily dose by Week 25 (EOT) • By Week 25 (EOT) • 42% (5/12) of patients with a high anti-dsDNA titer norm

  9. Slide 9: Zetomipzomib Decreased Urinary CD163, an Inflammatory Marker Correlating With UPCR

    MISSION Phase 2: Zetomipzomib Decreased Urinary CD163*, an Inflammatory Marker Shown to Correlate With UPCR (n=13†) uCD163 Highest observation Correlation Between UPCR and uCD163 Upper Quartile (Q3) x Mean EOT Median 1.5 uCD163 (x1000 ng/mmol) Lower Quartile (Q1) EOS 1 LOG10 (uCD163) Minimum Value 0

  10. Slide 10: MISSION Phase 2: Safety and Tolerability

    MISSION Phase 2: Safety and Tolerability Adverse Events, n (%) MISSION Phase 2 Zetomipzomib N=21 Most common TEAE: Injection-site reaction 15 (71.4) TEAE leading to study drug discontinuation 4 (19.0)† Serious TEAE 2 (9.5)‡ Grade ≥3 TEAE 6 (28.6)* Opportunistic Infections 0 (0) Death 0 (0) † 3 relat

  11. Slide 11: Conclusions

    Conclusions In the MISSION open-label study, zetomipzomib treatment demonstrated clinically meaningful renal responses in LN patients who had not responded to SOC therapy Zetomipzomib once-weekly demonstrated a favorable safety and tolerability profile with no evidence of immunosuppression (no clini

Kezar Life Sciences — Technical Presentation (2023) on 6ix